IRIX IRIDEX Corp Forecast, Technical & Fundamental Analysis
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases... Show more
IRIX is expected to report earnings to fall 33.33% to -1 cents per share on August 06
Q2'26
Est.
$-0.02
Q1'26
Beat
by $0.02
Q4'25
Beat
by $0.01
Q3'25
Missed
by $0.03
Q2'25
Beat
by $0.03
The last earnings report on May 19 showed earnings per share of -2 cents, beating the estimate of -5 cents. With 27.29K shares outstanding, the current market capitalization sits at 20.45M.
A.I. Advisor
published General Information
General Information
a manufacturer of light-based medical systems and delivery devices
A.I.dvisor tells us that IRIX and NTRA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IRIX and NTRA's prices will move in lockstep.
IRIX in upward trend: price rose above 50-day moving average on June 01, 2026
IRIX moved above its 50-day moving average on June 01, 2026 date and that indicates a change from a downward trend to an upward trend. In of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 22, 2026. You may want to consider a long position or call options on IRIX as a result. In of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The 10-day moving average for IRIX crossed bullishly above the 50-day moving average on June 03, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IRIX advanced for three days, in of 209 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for IRIX moved out of overbought territory on June 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where IRIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IRIX broke above its upper Bollinger Band on June 01, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IRIX entered a downward trend on May 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IRIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: IRIX's P/B Ratio (270.270) is very high in comparison to the industry average of (10.753). P/E Ratio (0.000) is within average values for comparable stocks, (61.509). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.702). IRIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (0.383) is also within normal values, averaging (23.786).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
